5 Key Takeaways

• 1

  Low-coverage whole genome sequencing (lcWGS) can predict bowel cancer risk in patients with ulcerative colitis (UC) by analyzing precancerous growths.

• 2

  The study analyzed 270 low-grade dysplasia samples from 122 UC patients, identifying progressors and non-progressors based on advanced neoplasia development.

• 3

  CNA burden was significantly higher in progressors, making it a strong predictor of advanced neoplasia risk compared to traditional clinical risk factors.

• 4

  Combining genomic and clinical data improves predictive accuracy for bowel cancer risk in UC patients.

• 5

  Future research will validate findings in larger cohorts and assess lcWGS integration into routine UC surveillance programs.